Influences on Psychiatrist Prescribing of Antipsychotics

对精神科医生开抗精神病药处方的影响

• 批准号: 8233719
• 负责人: JULIE Marie DONOHUE
• 金额: $ 63.55万
• 依托单位: HARVARD MEDICAL SCHOOL
• 依托单位国家: 美国
• 财政年份: 2012
• 资助国家: 美国
• 起止时间: 2012-04-01 至 2015-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8233719
• 关键词: Accounting; Address; Adopted; Adoption; Antipsychotic Agents; Behavior; Caring; Characteristics; Clinical; Communities; Consensus; County; Data; Drug Prescriptions; Economics; Effectiveness; Elderly; Evidence Based Medicine; Expenditure; Exposure to; Government Financing; Growth; Health; Heterogeneity; Hospitals; Income; Individual; Intervention; Link; Manufacturer Name; Marketing; Masks; Medicaid; Medicare; Medicare/Medicaid; Mental disorders; Mood Disorders; New Agents; Organizational Affiliation; Organizational Policy; Patients; Pattern; Pharmaceutical Preparations; Pharmacologic Substance; Pharmacy facility; Physicians; Policies; Policy Maker; Population; Provider; Psychiatrist; Psychopharmacology; Residencies; Risk; Safety; Sales; Sampling; Schizophrenia; Speed; Training; Training and Education; United States Food and Drug Administration; Variant; Visit; atypical antipsychotic; behavior change; clinical practice; comparative effectiveness; cost effectiveness; demographics; drug efficacy; effectiveness research; health care service organization; improved; olanzapine; prior authorization; programs; psychopharmacologic; response; trend

DESCRIPTION (provided by applicant): Use of antipsychotic medications, the top selling medication class in 2009 and a primary driver of recent growth in state Medicaid pharmacy expenditure, has changed dramatically in the past two decades since the introduction of several atypical antipsychotics. Recently, Food and Drug Administration (FDA) warnings and comparative effectiveness research have pointed to elevated risks associated with use of atypicals and have raised questions about their cost-effectiveness. Little is known about how psychiatrists adopt new medications, or whether and how they change their practice patterns when new evidence emerges on psychiatric drug efficacy and/or safety. Importantly, we know little about the provider-, organizational- and policy-level factors that promote or inhibit psychiatrists' response to new safety and efficacy information. Using unique physician-level data on antipsychotic prescribing for all psychiatrists who prescribe antipsychotic medications from IMS Health linked with physician characteristics from the AMA Masterfile, physician affiliations with health care organizations from the Health Care Organization Services data, data on pharmaceutical manufacturers' promotional efforts, data on local environmental characteristics, and data on state Medicaid and Medicare policies on coverage of antipsychotics for the period 1997-2011, we will: 1) characterize the speed of adoption of new antipsychotic medications among psychiatrists and identify factors associated with early vs. late adoption; 2) examine psychiatrists' responses to comparative effectiveness research and safety information and identify factors associated with a psychiatrist's response; and 3) evaluate whether commercial influences (e.g., manufacturer promotion) and policy factors, such as Medicaid and Medicare drug coverage restrictions, influence psychiatrists' responses to drug information. Addressing concerns about the quality and efficiency of psychopharmacologic care for people with mental disorders depends on changing the behavior of individual physicians. However, we do not know when and how to target interventions nor which interventions are most effective. Should we find that much of the variation in psychiatrists' prescribing is explained by where and when they trained then efforts to improve psychiatric residency training in psychopharmacology and evidence-based medicine should be intensified. Alternatively, if organizational factors, pharmaceutical promotion and/or policy factors explain much of the variation in prescribing behaviors, such findings would motivate interventions at the organizational and policy-level. . PUBLIC HEALTH RELEVANCE: By characterizing psychiatrist adoption of new antipsychotic medications and identifying factors that influence psychiatrist response to comparative effectiveness and safety information, such as education and training, organizational characteristics, pharmaceutical manufacturer promotion, and policy factors, this study will provide important data on how psychiatrists make prescribing decisions and respond to new clinical information. Understanding how psychiatrists adopt new medications and new evidence into their practice is critical to developing clinical and policy interventions to improve the efficiency and quality of psychiatric medication use.

描述（由申请人提供）：自引入几种非典型抗精神病药物以来，抗精神病药物的使用在过去二十年中发生了巨大变化，抗精神病药物是2009年最畅销的药物类别，也是最近州医疗补助药房支出增长的主要驱动力。最近，美国食品和药物管理局（FDA）的警告和比较有效性研究指出，与使用药物相关的风险增加，并对其成本效益提出了质疑。关于精神科医生如何采用新的药物，或者当出现关于精神科药物疗效和/或安全性的新证据时，他们是否以及如何改变他们的实践模式，我们知之甚少。重要的是，我们对促进或抑制精神科医生对新的安全性和有效性信息的反应的提供者、组织和政策层面的因素知之甚少。使用来自IMS Health的所有开具抗精神病药物的精神病医生的抗精神病药物处方的唯一医生级数据，与来自AMA主文件的医生特征，来自医疗保健组织服务数据的医疗保健组织的医生从属关系，制药商促销工作的数据，当地环境特征的数据，以及1997-2011年期间关于抗精神病药物覆盖范围的州医疗补助和医疗保险政策的数据，我们将：1）描述精神科医生采用新抗精神病药物的速度，并确定与早期和晚期采用相关的因素; 2）检查精神科医生对比较有效性研究和安全性信息的反应，并确定与精神科医生反应相关的因素;以及3）评估商业影响（例如，制造商促销）和政策因素，如医疗补助和医疗保险的药物覆盖范围限制，影响精神科医生对药物信息的反应。解决对精神障碍患者的精神药理学护理质量和效率的担忧取决于改变个别医生的行为。然而，我们不知道何时和如何有针对性地采取干预措施，也不知道哪些干预措施最有效。如果我们发现精神科医生开药的差异很大程度上是由他们在哪里和何时接受培训来解释的，那么应该加强精神药理学和循证医学方面的精神科住院医师培训。或者，如果组织因素，药品促销和/或政策因素解释了处方行为的变化，这些发现将激励在组织和政策层面的干预。. 公共卫生相关性：通过表征精神科医生采用新的抗精神病药物，并确定影响精神科医生对比较有效性和安全性信息的反应的因素，如教育和培训，组织特征，制药商推广和政策因素，本研究将提供关于精神科医生如何做出处方决策和对新临床信息做出反应的重要数据。了解精神科医生如何在实践中采用新药物和新证据，对于制定临床和政策干预措施以提高精神科药物使用的效率和质量至关重要。